Analyst Price Target is $14.75
▲ +42.79% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Roivant Sciences in the last 3 months. The average price target is $14.75, with a high forecast of $23.00 and a low forecast of $10.00. The average price target represents a 42.79% upside from the last price of $10.33.
Current Consensus is
The current consensus among 8 polled investment analysts is to moderate buy stock in Roivant Sciences. This Moderate Buy consensus rating has held steady for over two years.
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.